AI药物开发启动Pathos AI关闭2.37M投资。
Pathos AI Inc. 今天的宣布公司以30亿美元估值，拥有融资2.37亿美元的资金。
制药巨头布里斯托尔·迈尔斯·斯基布(英语：Bristol Myers Squibb Co.)领导了E系列赛，有几位不知名的回归者参加。 Pathos的投资者名册包括大名，如AstraZeneca plc、NEA和General Atlantic。
Pathos正在利用一个名为Foundry的人工智能平台来开发癌症药物。 据该公司称，该软件可访问约200个网点的肿瘤数据。 还吸收了Pathos药物开发方案所产生的信息。 Foundry分析这些数据集，以帮助公司的研究人员更有效地开展工作。
制药研究计划有时会产生上百个药物候选者，分子，有可能被转化为药物。 铸币局使用AI agents确定最有前途的分子。 从那里，它可以确定哪些病人可以从每次治疗中受益最大。
Pathos还用Foundry来计划它所开发的药物的临床试验。 称公司的试验是“生物标志驱动的”。 生物标志是生物现象，可以提供对药物有效性的洞察。 它们的形式多种多样，从蛋白质到血压等病人的度量。
称 Pathos首席执行官Iker Huerga。 “基金会从根本上加快了我们查明很有前途的临床资产并将其纳入我们管道的能力。”
Pathos将利用其E系列回合资助其药物开发工作。 该公司说，其“关键优先事项”是其JSKN016方案，其目的是在所谓的抗体-药物共生治疗基础上发展癌症疗法。
抗体是识别致病细胞并与之结合的分子。 一旦一个抗体被附着在细胞上，它就起到能引起免疫系统注意的一类信标的作用。 免疫细胞随后找到抗体并摧毁其附着的细胞。
抗体-药物结合剂使用该方法的一种变体来治疗癌症。 抗原、有疗效的分子。 抗体-药物结合物附着于癌细胞上并导致它们能吸收抗原，从而中和。
Pathos还将利用资本资助另外三个药物方案。 其中一项举措是与去年投资该公司的AstraZeneca合作。 该联合方案寻求开发一种所谓的ER PROTAC药物，利用细胞内置的材料回收机制来治疗癌症。
布里斯托尔·迈尔斯·斯基布(英语：Bristol Myers Squibb)今天对Pathos 宣布的投资是公司之间更广泛的伙伴关系的一部分。 合作还涉及公开交易的医疗数据提供者Tempus AI Inc.。
Pathos将在五年内支付5 500万美元，以发放从神经疾病患者收集的匿名数据。 前公司将利用Foundry来分析这些信息来更好地了解疾病生物学。 此外，还将向布里斯托·迈尔斯·斯基布提供Foundry和数据集。 制药者会利用这些药来改进其临床试验，并找出最有可能从新药中受益的病人。
图像：未溅出
SiliconANGLE联合创始人John Furrier的留言：
支持我们的使命，通过与CUBE社区接触，保持内容的开放和自由。 加入CUBE的校友信托网络，其中技术领导者相互连接，分享情报并创造机会。
- 15M+观看CUBE视频，为跨越AI、云、网络安全等的对话提供动力
- 11.4k+CUBE校友——通过一个独特的信任网络，与11,400多位技术和企业领袖建立联系，塑造未来
你是AWS客户吗？在财务上支持SiliconANGLE，从我们的市场门户页面和链接购买您的AWS服务：https://siliconangle.com/aws-marketplace/
关于 SiliconANGLE 媒体
SiliconANGLE Media由技术视觉家John Furrier和Dave Vellante所创立，构建了产业领先数字媒体品牌的动态生态系统，达到了1500+百万精英技术专业人士。 我们的新专有CUBE AI Video Cloud正在观众互动中突破地步
本文由 AI宝库自动抓取并翻译，版权归原作者所有；如需查看原文请点下方链接。
AI drug development startup Pathos AI closes $237M investment
Pathos AI Inc. today announced that it has raised $237 million in funding at a $3 billion valuation.
Pharmaceutical giant Bristol Myers Squibb Co. led the Series E round with participation from several unnamed returning backers. Pathos’ investor roster includes big names such as AstraZeneca plc, NEA and General Atlantic.
Pathos is developing cancer drugs using an artificial intelligence platform called Foundry. According to the company, the software has access to about 200 petabytes of oncological data. It also ingests the information generated by Pathos’ drug development programs. Foundry analyzes those datasets to help the company’s researchers pursue their work more efficiently.
Pharmaceutical research programs sometimes produce hundreds of drug candidates, molecules that can potentially be turned into medicines. Foundry uses AI agents to pinpoint the most promising molecules. From there, it identifies the patients who could benefit the most from each therapy.
Pathos also uses Foundry to plan clinical trials for the drugs that it develops. The company says that its trials are “biomarker-driven.” Biomarkers are biological phenomena that can provide insight into the effectiveness of a drug. They take a wide variety of forms ranging from proteins to patient metrics such as blood pressure.
“We are building a platform to systematically improve the probability of success in drug development,” said Pathos Chief Executive Officer Iker Huerga. “Foundry has fundamentally accelerated our ability to identify highly promising clinical assets and integrate them into our pipeline.”
Pathos will use its Series E round to finance its drug development efforts. The company stated that its “key priority” is its JSKN016 program, which aims to develop a cancer therapy based on a so-called antibody-drug conjugate.
Antibodies are molecules that identify disease-causing cells and bind to them. Once an antibody is attached to a cell, it functions as a kind beacon that draws the attention of the immune system. Immune cells subsequently find the antibody and destroy the cell to which it’s attached.
Antibody-drug conjugates use a variation of that approach to treat cancer. They’re effectively upgraded antibodies that contain an antigen, a molecule with therapeutic properties. Antibody-drug conjugates attach to cancer cells and cause them to absorb the antigen, which neutralizes them.
Pathos will also use the capital to finance three other drug programs. One of those initiatives is a collaboration with AstraZeneca, which invested in the company last year. The joint program seeks to develop a so-called ER PROTAC drug, which harnesses cells’ built-in material recycling mechanism to treat cancer.
The investment from Bristol Myers Squibb that Pathos announced today is part of a broader partnership between the companies. The collaboration also involves Tempus AI Inc., a publicly traded medical data provider .
Pathos will pay Tempus $55 million over five years to license anonymized data collected from patients with neurological conditions. The former company will analyze that information using Foundry to gain a better understanding of disease biology. Additionally, it will make both Foundry and the dataset available to Bristol Myers Squibb. The drugmaker will use them to improve its clinical trials and identify patients most likely to benefit from new drugs.
Image: Unsplash
A message from John Furrier, co-founder of SiliconANGLE:
Support our mission to keep content open and free by engaging with theCUBE community. Join theCUBE’s Alumni Trust Network, where technology leaders connect, share intelligence and create opportunities.
- 15M+ viewers of theCUBE videos, powering conversations across AI, cloud, cybersecurity and more
- 11.4k+ theCUBE alumni — Connect with more than 11,400 tech and business leaders shaping the future through a unique trusted-based network
Are you an AWS customer? Support SiliconANGLE financially by buying your AWS services from our Marketplace portal page and links: https://siliconangle.com/aws-marketplace/
About SiliconANGLE Media
Founded by tech visionaries John Furrier and Dave Vellante, SiliconANGLE Media has built a dynamic ecosystem of industry-leading digital media brands that reach 15+ million elite tech professionals. Our new proprietary theCUBE AI Video Cloud is breaking ground in audience interaction, leveraging theCUBEai.com neural network to help technology companies make data-driven decisions and stay at the forefront of industry conversations.
Auto-fetched and translated by AI Gem Box. All rights belong to the original author.